Novartis brings Lutathera to adolescents with rare cancer in first for radioligand class

No­var­tis’ Lu­tathera is now the first ra­dio­phar­ma­ceu­ti­cal ap­proved for ado­les­cents with a rare can­cer found in the gut.

The ra­di­oli­gand ther­a­py won a la­bel ex­pan­sion on Tues­day for pa­tients 12 years and old­er with so­mato­statin re­cep­tor-pos­i­tive gas­troen­teropan­cre­at­ic neu­roen­docrine tu­mors, or GEP-NETs. Neu­roen­docrine tu­mors are ex­ceed­ing­ly rare, with on­ly a few thou­sand di­ag­noses per year in the US, ac­cord­ing to MD An­der­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.